Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Maintenance therapy 'cuts chances of lymphoma relapse'

  • Comment

Treating follicular lymphoma (FL) with “maintenance therapy” can halve the likelihood of a relapse, experts have found.

The new approach involved 1,200 patients given standard chemotherapy plus low doses of the targeted antibody drug rituximab.

The French-led trial found that after two years, 82% of patients who received the two-monthly maintenance therapy were still symptom-free. Patients not given the ongoing treatment were twice as likely to relapse.

More than 15,000 people are affected by FL in the UK.

European regulators have now approved use of the drug, marketed as MabThera, as a maintenance treatment for FL. However, it is not yet known if the approach will be adopted by the NHS.

First it has to be assessed by the National Institute for Health and Clinical Excellence (NICE), which judges the effectiveness of new treatments in England and Wales. A decision is expected next year.

A key consideration will be cost. Maintenance therapy with rituximab costs £611 per month, or £7,332 a year.

Professor Graham Jackson, consultant haematologist at the Freeman Hospital, Newcastle, said: “The approval of rituximab as first-line maintenance therapy is not only a significant improvement in the way we can manage FL, it also moves us another step closer to a turning point in the way in which cancer is treated.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs